Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK536689PMID: 30694621
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 17141-74-1
Drug Levels and Effects
Summary of Use during Lactation
Because sodium zirconium cyclosilicate is not orally absorbed it is unlikely to reach the breastmilk or adversely affect the breastfed infant. No special precautions are required.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Sodium Zirconium Cyclosilicate
CAS Registry Number
17141-74-1
Drug Class
Breast Feeding
Lactation
Milk, Human
Cation Exchange Resins
Chelating Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.[Clin J Am Soc Nephrol. 2019]Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.Spinowitz BS, Fishbane S, Pergola PE, Roger SD, Lerma EV, Butler J, von Haehling S, Adler SH, Zhao J, Singh B, et al. Clin J Am Soc Nephrol. 2019 Jun 7; 14(6):798-809. Epub 2019 May 20.
- Review Sodium Zirconium Cyclosilicate (ZS-9): A Novel Agent for the Treatment of Hyperkalemia.[Pharmacotherapy. 2016]Review Sodium Zirconium Cyclosilicate (ZS-9): A Novel Agent for the Treatment of Hyperkalemia.Linder KE, Krawczynski MA, Laskey D. Pharmacotherapy. 2016 Aug; 36(8):923-33. Epub 2016 Aug 2.
- Zirconium cyclosilicate: An oral sorbent for potassium, four decades in the making.[Artif Organs. 2022]Zirconium cyclosilicate: An oral sorbent for potassium, four decades in the making.Ash SR. Artif Organs. 2022 Jun; 46(6):1192-1197. Epub 2022 Apr 19.
- Radiopacity of sodium zirconium cyclosilicate on CT imaging.[CEN Case Rep. 2021]Radiopacity of sodium zirconium cyclosilicate on CT imaging.Kolesnik M, Berezovsky D, Sayegh M, Samarneh M. CEN Case Rep. 2021 Nov; 10(4):559-562. Epub 2021 May 19.
- Review Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia.[Expert Opin Drug Metab Toxicol...]Review Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia.Packham DK, Kosiborod M. Expert Opin Drug Metab Toxicol. 2016 May; 12(5):567-73. Epub 2016 Apr 5.
- Sodium Zirconium Cyclosilicate - Drugs and Lactation Database (LactMed®)Sodium Zirconium Cyclosilicate - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...